MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 47 Publications

10 Customer Reviews

  • MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

    HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  • HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

     

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

  • JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

    LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

  • Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NHXmOZBHfW6ldHnvckBCe3OjeR?= M2XmZlI2KM7:TR?= MYHEUXNQ MknwTY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvOSEQvF2= MkXJNlQ3QTd2OU[=
HL-60 M3u4b2N6fG:2b4jpZ{BCe3OjeR?= M3\zRVQxKM7:TR?= M1TmeFQ5KGh? MWHEUXNQ MlfiTWM2ODxzMDFOwG0> NWK1XnNPOjR4OUe0PVY>
SMMC-7721 MUXDfZRwfG:6aXOgRZN{[Xl? M3fIUVQxKM7:TR?= M{fJS|Q5KGh? M2eyTGROW09? MWLJR|UxRTdwMTFOwG0> M3[1SVI1Pjl5NEm2
A-549 MWjDfZRwfG:6aXOgRZN{[Xl? NGPSTlI1OCEQvF2= MWm0PEBp M3;BR2ROW09? MVPJR|UxRDFyIN88US=> MnnrNlQ3QTd2OU[=
MCF-7 NFzkWJdEgXSxdH;4bYMhSXO|YYm= NULmZoo{PDBizszN MU[0PEBp MoTySG1UVw>? MV\JR|UxRTdwMzFOwG0> M1;zb|I1Pjl5NEm2
SW-480 MY\DfZRwfG:6aXOgRZN{[Xl? NXW1SWdKPDBizszN NFzqSGE1QCCq MmrsSG1UVw>? MV7JR|UxRTRizszN NYew[oliOjR4OUe0PVY>
NCI-H929 NXT6NGFqS3m2b4TvfIlkKEG|c3H5 MoLNNUDPxE1? MlvDO|IhcA>? NIK2R4ZFVVOR MoLSTWM2OD1yLkG3JO69VQ>? MW[yOFYzPTB6OB?=
293T M1r0UGN6fG:2b4jpZ{BCe3OjeR?= MkPtNVAh|ryP NWHuU3VQPzJiaB?= NHPpcHFFVVOR Mm[4TWM2ODx{IN88US=> M4DnT|I1PjJ3MEi4
293T M1nYfmZ2dmO2aX;uJGF{e2G7 MVuxNEDPxE1? NHnob4IzPCCq MVjEUXNQ M3;MN21w\GW{YYTlcJkhcW6mdXPld{Bp\WG2LYPoc4NsKCB? M3HrPFI1PjJ3MEi4
HeLa MkPuT4lv[XOnIFHzd4F6 NE\KfWkyOCEQvF2= NYnvfphMOSCq NFHjOXVFVVOR MlnlTY5lfWOnczDQRXJRKGOuZXH2ZYdmKGK7IHnubIljcXSrbnegdJJwe2Wjc3;t[UBi[3Srdnn0fS=> MkLBNlQ{OjF6M{O=
MDA-MB-231 NHP0NGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTwOm5sOSEQvF2= NET5SJk4OiCq NInHWGhFVVOR NH30eXFKSzVyPUCuNVgh|ryP MWGyOFE2OzJyNh?=
MCF-7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\XXVEh|ryP M1viWlczKGh? MYLEUXNQ NUXBemlrUUN3ME2wMlE{KM7:TR?= MYqyOFE2OzJyNh?=
MCF10A NWTvOHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C0fVEh|ryP NVr6dXpEPzJiaB?= NIrUclRFVVOR MmnSTWM2OD1yLkK5JO69VQ>? MVuyOFE2OzJyNh?=
HEK-293 MUjLbY5ie2ViQYPzZZk> MlHWNkBidmRiMkCg{txO NGDwToQzKGh? NHzPeo9FVVOR NHjaN2NKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= M4LBbFI{PTRyN{mw
Calu6 M1\PU2Z2dmO2aX;uJGF{e2G7 NHn6dncyOCEQvF2= MmPZNVghcA>? MmHsSG1UVw>? NGfJfXpUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=> M2fHSFI{PTB4NEi2
IFN-gamma-induced RAW264.7 MXvGeY5kfGmxbjDBd5NigQ>? M1S5W2ROW09? MkPoTY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvODd5IN88US=> M1S1ZVIzOjd5Mke3
IPC227F NV\DPYV[S3m2b4TvfIlkKEG|c3H5 M3;CZlEh|ryP NX\JTm9kPDhiaB?= M4PrSmROW09? NEDWZWxKSzVyPUCuNFc4KM7:TR?= NXnsXI9WOjF7MkS1Nlg>
Hepa-1c1c7 M332ZmZ2dmO2aX;uJGF{e2G7 MVuyOUDPxE1? M1z2fVYhcA>? NYTNTG02TE2VTx?= M4r0V2lv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw> MXeyNFM6OjV2NB?=
COS-7 M1jFcGN6fG:2b4jpZ{BCe3OjeR?= NG\6fHAyOCEQvF2= M3njfGROW09? MnLFTWM2ODxzMDFOwG0> NFnoWIYyQDB6OEC5Oy=>
HuH-7 NEjRS4hEgXSxdH;4bYMhSXO|YYm= MoXFNVAh|ryP M4nnNGROW09? MXvJR|UxRDFyIN88US=> MoDpNVgxQDhyOUe=
OCI-Ly3 NXPTNFFQTnWwY4Tpc44hSXO|YYm= NXmzW3RzOTBizszNxsA> Mn\3OEBp NEDEUohFVVOR M2frdGlv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP MYmxPFAzPDFzMx?=
A2780 cDDP NIW3SG5CeG:ydH;zbZMhSXO|YYm= M4TOflI1KGh? MWnEUXNQ NID5NWFKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnjpZol1cW6pIGDUSW4h\GWpcnHkZZRqd25? NXy4c5JEOTd4OESwNVg>
LPS-stimulated RAW264.7 cells M161fmZ2dmO2aX;uJGF{e2G7 MWfEUXNQ M13OdGlvcGmkaYTzJG5HNWujcIDhRkBFVkFiYnnu[Ilv\w>? NGq0foYyPzRyN{K3Oy=>
PC12 NIrlU4xHfW6ldHnvckBCe3OjeR?= NULYOVBbOTByIN88UeKh NV3pb2R6OjRiaB?= MmC0SG1UVw>? M{[xUWlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk> M1izO|E4OTV6NEW0
PC3 M36zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv4NlAh|ryP NHTlSlE1QCCq NXLWWnFjTE2VTx?= NHPBeFJKSzVyPUCuOkDPxE1? MUmxOlY5PjV|Nx?=
LP-1 MXnBdI9xfG:|aYOgRZN{[Xl? NEPZR2M{ODBibl2= M4\VSlI1KGh? NH75TJBFVVOR MVjJcoR2[2W|IHHwc5B1d3OrczDifUBqdmO{ZXHzbY5oKGOuZXH2[YQhWEGUUDDs[ZZmdCCjbnSgdoVlfWOrbnegUYNtNTFicILveIVqdiCuZY\lcC=> MnnkNVU6PTh3OEm=
ES6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq1c5hrUUN3ME2wMlAyOzB4IN88US=> Mk\MV2FPT0WU
A101D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEOyO|kh|ryP NYG5WIV{W0GQR1XS
OCUB-M NIjQXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLPe4pKSzVyPUCuNFM4OzdizszN NFfp[XJUSU6JRWK=
LB2518-MEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LFPWlEPTB;MD6wN|c3KM7:TR?= MVLTRW5ITVJ?
SH-4 M3XIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fERWlEPTB;MD6wOFMyKM7:TR?= M1HuVHNCVkeHUh?=
KNS-42 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn76TWM2OD1yLkC0OFQyKM7:TR?= NV\YdIVuW0GQR1XS
DSH1 M3zzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzZSVBSUUN3ME2wMlA2Ojh7IN88US=> M2SwOXNCVkeHUh?=
NTERA-S-cl-D1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf1cYxKSzVyPUCuNFU4PzJizszN NETjfJpUSU6JRWK=
D-542MG M1;IR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES4foVKSzVyPUCuNFU6PTdizszN M4npcHNCVkeHUh?=
KS-1 NWnWPHZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO2TWM2OD1yLkC2OFU5KM7:TR?= NIPG[oZUSU6JRWK=
BL-41 M4rZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfLfFZKSzVyPUCuNFY6PDdizszN MW\TRW5ITVJ?
LXF-289 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2yTWM2OD1yLkC3NFY3KM7:TR?= M1TJN3NCVkeHUh?=
D-247MG Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD1yLkC3NlA6KM7:TR?= NIXBfIFUSU6JRWK=
MMAC-SF NF\rbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULQenJZUUN3ME2wMlA4OjZ6IN88US=> M{L0fXNCVkeHUh?=
CP66-MEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlexTWM2OD1yLkC3OUDPxE1? NVHIeHhwW0GQR1XS
LB771-HNC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf1TWM2OD1yLkC4NFM3KM7:TR?= NWrYU5Y1W0GQR1XS
no-10 NH3M[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHrdG1KSzVyPUCuNFg6ODlizszN NHnHSIdUSU6JRWK=
A388 NUjGNJF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LzbmlEPTB;MD6wPVA3PSEQvF2= MlWwV2FPT0WU
OPM-2 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXsd2dKSzVyPUCuNVA1PzRizszN NF[zb|hUSU6JRWK=
OVCAR-4 M1nUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnYTWM2OD1yLkGwPVM5KM7:TR?= Mle3V2FPT0WU
HOP-62 NUjrZpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHxTWM2OD1yLkGwPVQ6KM7:TR?= MX\TRW5ITVJ?
ML-2 NFLlfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6U5BKSzVyPUCuNVE5ODZizszN NFH3N|ZUSU6JRWK=
UACC-257 NFfNTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfP[WxKUUN3ME2wMlEyQTJ5IN88US=> NFHDOpRUSU6JRWK=
NEC8 NGXOcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pqb2lEPTB;MD6xNVk6PSEQvF2= NFfRO2RUSU6JRWK=
ONS-76 NEnIdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3ad|B4UUN3ME2wMlEzQTN3IN88US=> M4jjPXNCVkeHUh?=
KE-37 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHLTWM2OD1yLkGzNlc5KM7:TR?= NVrs[ndmW0GQR1XS
HT-144 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ji[WlEPTB;MD6xN|g6PSEQvF2= NY\xNHl7W0GQR1XS
LB2241-RCC M3LUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMUSyOFch|ryP M1[1R3NCVkeHUh?=
TE-5 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPsdFdKSzVyPUCuNVQzPzhizszN M{TId3NCVkeHUh?=
KINGS-1 M1X3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOyTWM2OD1yLkG0O|kh|ryP Mle4V2FPT0WU
NCI-H69 NEXFV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUWxOFEh|ryP NHi4[FdUSU6JRWK=
CAS-1 M{HvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfqUW9KSzVyPUCuNVU1QDJizszN NUTINWt1W0GQR1XS
D-263MG NWL6SppDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTHS3FpUUN3ME2wMlE3ODB4IN88US=> M2j0VHNCVkeHUh?=
A253 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvhc|k6UUN3ME2wMlE3OTJ6IN88US=> MnmwV2FPT0WU
PF-382 M4jn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWeyOpZ4UUN3ME2wMlE3PzB4IN88US=> NEfEN4VUSU6JRWK=
CESS NYOzZ|B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjbGZrUUN3ME2wMlE4ODZizszN Ml7vV2FPT0WU
MZ2-MEL NF\KTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXWTWM2OD1yLkG3OVU6KM7:TR?= M3uxR3NCVkeHUh?=
HEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfmTWM2OD1yLkG4OVE4KM7:TR?= MV;TRW5ITVJ?
D-392MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPJUmFKSzVyPUCuNVkyOTVizszN M4[2UXNCVkeHUh?=
SK-LMS-1 M3W2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMUmzNFMh|ryP Mnm5V2FPT0WU
GI-ME-N MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL5fIlKSzVyPUCuNVk{ODZizszN MXXTRW5ITVJ?
LB831-BLC NFvL[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LiNGlEPTB;MD6xPVM1KM7:TR?= MYnTRW5ITVJ?
DU-4475 NIf0OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLWTWM2OD1yLkG5OlU5KM7:TR?= NHnadnlUSU6JRWK=
IST-SL1 NI\YeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKyeIdoUUN3ME2wMlIxODl2IN88US=> NYr2SplvW0GQR1XS
GAK NWL2PJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMkC1N|Qh|ryP MYDTRW5ITVJ?
EW-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDCTWM2OD1yLkKxNFQ4KM7:TR?= NUSyO2l{W0GQR1XS
LAMA-84 NFvEOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnBPVVQUUN3ME2wMlIyQDVzIN88US=> MVzTRW5ITVJ?
SK-UT-1 M2fvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TLb2lEPTB;MD6yNlA1QSEQvF2= MVXTRW5ITVJ?
VA-ES-BJ NXqzZ2NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\UOJVJUUN3ME2wMlIzOjV5IN88US=> NYXVPW95W0GQR1XS
ACN NYXmcJZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PQd2lEPTB;MD6yNlY{QCEQvF2= NYS1cXhXW0GQR1XS
SK-PN-DW M2PaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrydHdKSzVyPUCuNlMyQSEQvF2= MYfTRW5ITVJ?
HD-MY-Z MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVficFVJUUN3ME2wMlI{OzB|IN88US=> MkPHV2FPT0WU
LB373-MEL-D NV\tWnd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnBXYtKSzVyPUCuNlQyQThizszN MmTxV2FPT0WU
COLO-829 M2nUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHPTWM2OD1yLkK0NlU4KM7:TR?= MX3TRW5ITVJ?
ES8 NXfxOY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HpN2lEPTB;MD6yOFc3OyEQvF2= MYTTRW5ITVJ?
RXF393 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqxTWM2OD1yLkK1NFE2KM7:TR?= MnfJV2FPT0WU
TK10 NUDheYZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnfmlEPTB;MD6yOVQ{PSEQvF2= NXz3PGFRW0GQR1XS
LOUCY MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonPTWM2OD1yLkK1OFU3KM7:TR?= MnvMV2FPT0WU
MZ7-mel MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7vOoFKSzVyPUCuNlY{PzRizszN NXnSOIdWW0GQR1XS
CP67-MEL Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7hRnZKSzVyPUCuNlY4OyEQvF2= M1rkdXNCVkeHUh?=
C2BBe1 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\rcGlEPTB;MD6yO|kxPyEQvF2= NVPseZFEW0GQR1XS
K052 NGjtPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG1S4ZKSzVyPUCuNlg6QSEQvF2= NITDcHFUSU6JRWK=
MOLT-16 NY\yfGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMkm1NlQh|ryP MmXMV2FPT0WU
KNS-81-FD NEjGOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm5TWM2OD1yLkOwN|I{KM7:TR?= MVvTRW5ITVJ?
CMK MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\HTWM2OD1yLkOxNVIh|ryP NITTWGhUSU6JRWK=
LAN-6 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jkPWlEPTB;MD6zNVMh|ryP NWLiUVlsW0GQR1XS
KLE MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwM{GzNFYh|ryP MmDrV2FPT0WU
NCCIT M3q2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vsUWlEPTB;MD6zNVc5OyEQvF2= MYrTRW5ITVJ?
HH M{fBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfmTWM2OD1yLkOyPFk4KM7:TR?= NWPaPYxUW0GQR1XS
TE-8 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rUTGlEPTB;MD6zOFI4QSEQvF2= MonwV2FPT0WU
GDM-1 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGToOI5KSzVyPUCuN|UyODRizszN M{PpbXNCVkeHUh?=
NCI-H747 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33nZmlEPTB;MD6zO|ExOyEQvF2= MnfBV2FPT0WU
NCI-H1092 M3;uOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwM{i4OFQh|ryP MVPTRW5ITVJ?
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfNeXBKSzVyPUCuN|k5OzdizszN MYDTRW5ITVJ?
NB17 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOXYxMUUN3ME2wMlQzQTdizszN MW\TRW5ITVJ?
LC4-1 NYPoWodxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwNEO2NFch|ryP NFXKXndUSU6JRWK=
TE-1 NV\oXVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\wRWM2UUN3ME2wMlQ2OTF7IN88US=> NGn0[XZUSU6JRWK=
KALS-1 NHnHPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITZXppKSzVyPUCuOFY2QDRizszN NXfmNpI2W0GQR1XS
CCRF-CEM NEjoPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3USJZjUUN3ME2wMlQ4Pjd2IN88US=> NF6xXINUSU6JRWK=
OS-RC-2 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrzXWJKSzVyPUCuOFc6PzJizszN NEC4UndUSU6JRWK=
A704 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjMfY1KSzVyPUCuOFg3QTJizszN MoPnV2FPT0WU
BB49-HNC MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfJS|FXUUN3ME2wMlQ6ODl4IN88US=> NE\SeZFUSU6JRWK=
EVSA-T MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLF[npKSzVyPUCuOFk6OTFizszN NV3YR3BpW0GQR1XS
Mo-T NVHRdld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwNUG3OlIh|ryP NIDueYFUSU6JRWK=
MONO-MAC-6 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm0PWY6UUN3ME2wMlU{PjFzIN88US=> M2f5SnNCVkeHUh?=
BB65-RCC NXfGdndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SwVmlEPTB;MD61OlgyOSEQvF2= NH;hZXVUSU6JRWK=
NCI-H1882 M17pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV75NHdYUUN3ME2wMlU6ODN4IN88US=> M{i4R3NCVkeHUh?=
TE-9 NV\rOGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;CVHFKSzVyPUCuOlExOzNizszN NFLMcFNUSU6JRWK=
NCI-H2126 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEexRY5KSzVyPUCuOlI3PjlizszN MoLRV2FPT0WU
SF268 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwNkW2OFEh|ryP NWnTcGdyW0GQR1XS
SW872 NELqTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvhfVJZUUN3ME2wMlY2PzJ7IN88US=> NX3OOoozW0GQR1XS
LS-513 M3m1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNk[3OVEh|ryP NVvNclZIW0GQR1XS
NCI-H1355 NVTyUHVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj4e2wzUUN3ME2wMlY5PjF7IN88US=> NI\QWmxUSU6JRWK=
BL-70 NUDoRpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnCOnpUUUN3ME2wMlY6Ozh6IN88US=> MWHTRW5ITVJ?
NCI-SNU-5 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HmOGlEPTB;MD62PVU1PSEQvF2= NH7YeHFUSU6JRWK=
SNU-C2B MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLFTWM2OD1yLkewO|M6KM7:TR?= NXfDOlU4W0GQR1XS
GB-1 NE\oeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jhV2lEPTB;MD63NlEzPCEQvF2= NFr3W5BUSU6JRWK=
CTB-1 M4T0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwN{e5OVUh|ryP NXOxVGN2W0GQR1XS
Becker NYjYW|FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zt[2lEPTB;MD63PVYzOSEQvF2= M2\Kb3NCVkeHUh?=
KM12 NU\4NIsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwOEW0OlYh|ryP NWjCWIM3W0GQR1XS
ES7 NFXDNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDRepNrUUN3ME2wMlg6PjVizszN NEfF[opUSU6JRWK=
COLO-684 NUe5PW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TmcWlEPTB;MD65NFY2QCEQvF2= NXfHNIxDW0GQR1XS
HCC2998 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq0TWM2OD1yLkmzPFU1KM7:TR?= MULTRW5ITVJ?
TE-10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzk[201UUN3ME2wMlk3PDNizszN MmjuV2FPT0WU
SF126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwOUi5O|Eh|ryP NIXLVpRUSU6JRWK=
EKVX NXvlUVE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOyfY1KSzVyPUGuNFM1PDJizszN M1jhcHNCVkeHUh?=
KARPAS-45 M3vHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwMESwNVYh|ryP NH7D[2dUSU6JRWK=
KGN Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMEWwOFUh|ryP MX;TRW5ITVJ?
ES1 MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jNcWlEPTB;MT6wO|kzOSEQvF2= M1\MRXNCVkeHUh?=
L-540 M37nO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;RTWM2OD1zLkGxPFM6KM7:TR?= NIrH[ItUSU6JRWK=
KURAMOCHI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwMUKzO|Qh|ryP NWXRdYlCW0GQR1XS
LU-65 M1zmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W1VWlEPTB;MT6xNlc2OyEQvF2= Mnn4V2FPT0WU
MFH-ino MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMUe1NFEh|ryP MVnTRW5ITVJ?
NCI-H23 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP1TIRKSzVyPUGuNlA1OSEQvF2= M3z4W3NCVkeHUh?=
IA-LM NH\jRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O5bGlEPTB;MT6yOFEyPiEQvF2= MlX1V2FPT0WU
PSN1 M13WcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfITWM2OD1zLkK3NFE3KM7:TR?= MXvTRW5ITVJ?
NCI-H719 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTvTWM2OD1zLkK3OFEyKM7:TR?= NGjGcYdUSU6JRWK=
SW684 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\RXFVKSzVyPUGuNlg3PTlizszN NF64cWtUSU6JRWK=
HCE-4 M1jrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXYTWM2OD1zLkOwNlIyKM7:TR?= Ml:5V2FPT0WU
EW-16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzSTWM2OD1zLkOxN|Q4KM7:TR?= NEG2W|JUSU6JRWK=
NCI-H128 NYn6U2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwM{W4NVQh|ryP NInVUHBUSU6JRWK=
HC-1 NF3CTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwM{ixO{DPxE1? NEHwUVZUSU6JRWK=
IST-MES1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjVWG5KSzVyPUGuOFAzODhizszN MXrTRW5ITVJ?
Raji Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4N4I4UUN3ME2xMlQyQDVizszN NV;IbHpPW0GQR1XS
DMS-114 NGTJRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwNES1N|kh|ryP MX3TRW5ITVJ?
GI-1 M4\QeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfvV|U5UUN3ME2xMlQ4OTNzIN88US=> NGHOUWRUSU6JRWK=
NCI-H2081 NIH3coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnnRZc5UUN3ME2xMlU2OTl4IN88US=> MWnTRW5ITVJ?
LC-1F NYfwZ411T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfsTWM2OD1zLkW1NVk5KM7:TR?= MYfTRW5ITVJ?
NCI-H2227 NX;lfZMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNkG1OlEh|ryP NFTrT4hUSU6JRWK=
D-502MG MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjqTWM2OD1zLk[3NlEyKM7:TR?= Mk\JV2FPT0WU
NCI-H2141 NH7YflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP5TWM2OD1zLk[3N|E4KM7:TR?= NYjyUYNMW0GQR1XS
LS-411N M{XLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGwfI9jUUN3ME2xMlY6QDB5IN88US=> NIHGblFUSU6JRWK=
SU-DHL-1 M{\SOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzTWM2OD1zLkexNlgyKM7:TR?= NHn4dI1USU6JRWK=
BB30-HNC NVXCOJRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOwTWM2OD1zLkeyOlg2KM7:TR?= MVfTRW5ITVJ?
TE-15 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCzTIlrUUN3ME2xMlkzOzd|IN88US=> NIfXbYtUSU6JRWK=
JVM-3 NGnSd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mx[2lEPTB;MT65N|kxPCEQvF2= NEHoR49USU6JRWK=
IST-SL2 NEjJWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXhWmF5UUN3ME2yMlAyOjV{IN88US=> MlvRV2FPT0WU
EW-18 NFfpVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3VUVRzUUN3ME2yMlAzOzN5IN88US=> M2X0UXNCVkeHUh?=
DJM-1 NGT6Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJwMEK1OVIh|ryP M1;rUXNCVkeHUh?=
no-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nh[2lEPTB;Mj6wN|ExPCEQvF2= NEPHZWZUSU6JRWK=
QIMR-WIL MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfhXIJZUUN3ME2yMlE3PzZ{IN88US=> MYDTRW5ITVJ?
MC-CAR M4TaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;YZnNPUUN3ME2yMlIzQTVizszN NXnFc|NZW0GQR1XS
KM-H2 M4HWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzuVpk4UUN3ME2yMlI6ODR|IN88US=> NV\MWHg1W0GQR1XS
ECC12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkftTWM2OD1{LkO3PVQh|ryP NFO1XFlUSU6JRWK=
HCE-T NGexb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfU[4dUUUN3ME2yMlQ1QDh|IN88US=> NVPxdYI3W0GQR1XS
MFM-223 NIS4cnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny4TWM2OD1{LkWwPFcyKM7:TR?= MX;TRW5ITVJ?
SW982 M3zLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\SZpJiUUN3ME2yMlUyPDhizszN NV\BcZUzW0GQR1XS
KG-1 NH7tfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJwOEi3PVEh|ryP MYrTRW5ITVJ?
ES4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjxemRKSzVyPUOuNFYyOTFizszN MUTTRW5ITVJ?
SCC-3 NV\Pd5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwMUC4OFgh|ryP NEjKNlBUSU6JRWK=
RH-1 M4\Qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz3V3BwUUN3ME2zMlM5PzR6IN88US=> NGr2dlVUSU6JRWK=
NCI-H748 NGHPR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXmd3RKSzVyPUOuOFQzPjZizszN MkTtV2FPT0WU
HCC2218 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWxTWM2OD1|LkS2PVM4KM7:TR?= MlPMV2FPT0WU
MEG-01 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHhV2IzUUN3ME2zMlU6PjhizszN MWLTRW5ITVJ?
NB12 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRTWM2OD1|LkW5PFg5KM7:TR?= M1Lj[XNCVkeHUh?=
SNB75 M3nsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwNkCxNFMh|ryP MoGyV2FPT0WU
KMS-12-PE NX61OpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm1NnNKSzVyPUOuOlc4OjNizszN MXLTRW5ITVJ?
SKM-1 NYfTSGFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32zV2lEPTB;Mz63NVM4PiEQvF2= NWfHNVhQW0GQR1XS
COLO-320-HSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyydFBKSzVyPUOuO|U3OzRizszN NHmydGJUSU6JRWK=
NKM-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfEUYFKSzVyPUOuO|c{PzhizszN NVHqOIZlW0GQR1XS
TE-6 M1j1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTsWnIyUUN3ME2zMlk1PTZzIN88US=> MoKyV2FPT0WU
D-336MG MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXoS3RXUUN3ME20MlAyOTZ4IN88US=> NI[1XJFUSU6JRWK=
NCI-H1650 NUjLO2lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\wNJBKSzVyPUSuNVU4QTdizszN M4\mc3NCVkeHUh?=
ES3 NXHETYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;vTWM2OD12LkOyPFI1KM7:TR?= M37n[nNCVkeHUh?=
YT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwM{W0NlQh|ryP MmXRV2FPT0WU
ES5 NIj3S2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfPUVFKSzVyPUSuOFAzPTVizszN MofSV2FPT0WU
LB647-SCLC M4H3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX64eFN3UUN3ME20MlU3OzB6IN88US=> MnPGV2FPT0WU
HAL-01 NEftU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRwNUewN|Qh|ryP NFvv[ZpUSU6JRWK=
LP-1 NEXtdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7TV21KSzVyPUSuO|I{PzFizszN NGD2cYJUSU6JRWK=
BC-1 NE\JWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTVwMEC0OFch|ryP NEnvTZZUSU6JRWK=
EB-3 NHfuRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiyTWM2OD13LkCzNFQyKM7:TR?= M3XrNHNCVkeHUh?=
GT3TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwMUe2OlIh|ryP NV;neIR{W0GQR1XS
NCI-H209 M4DSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q0XGlEPTB;NT6xPVM2OiEQvF2= M3nnfnNCVkeHUh?=
BT-474 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrXTWM2OD13LkKzNVAzKM7:TR?= MmnvV2FPT0WU
RKO NGn5bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnudm9vUUN3ME21MlI{PDJ{IN88US=> NGi0dGxUSU6JRWK=
SIMA MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjoTWM2OD13LkOwO|Y2KM7:TR?= NF7y[WFUSU6JRWK=
RL MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XPSGlEPTB;NT6zO|U1OSEQvF2= MnXBV2FPT0WU
GCIY NEjaXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVwNEeyN|Yh|ryP MWLTRW5ITVJ?
Calu-6 NVfpVIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xqe2lEPTB;NT62NlIh|ryP NIrUTYNUSU6JRWK=
ALL-PO NXXnN4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwNkO3PVUh|ryP NYLZfpZFW0GQR1XS
ARH-77 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHiZVhNUUN3ME21MlY4ODh5IN88US=> M{LxRnNCVkeHUh?=
A4-Fuk NFH2PGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nDXWlEPTB;Nj6wPFEyQCEQvF2= NYO5XmZnW0GQR1XS
NCI-H1581 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLsZnRmUUN3ME22MlI{QDR7IN88US=> MkXsV2FPT0WU
HUTU-80 NFHocGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnVTWM2OD14LkO2PFk4KM7:TR?= MV3TRW5ITVJ?
TGW MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv1TWM2OD14LkS1OVk{KM7:TR?= MmniV2FPT0WU
SK-N-FI M3P3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\pPWlEPTB;Nj60OVg2PCEQvF2= NH;FOmZUSU6JRWK=
U-266 NHPhb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;FcpR5UUN3ME22MlUyQTJ4IN88US=> NFPh[5dUSU6JRWK=
EM-2 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPqdXRMUUN3ME22MlY4ODl7IN88US=> M{fH[XNCVkeHUh?=
NMC-G1 NX;vdZh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DTPWlEPTB;Nj63NVg6PSEQvF2= NGXufI1USU6JRWK=
KASUMI-1 NYjnWFNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezZ|FKSzVyPU[uPFQ4QDdizszN MUDTRW5ITVJ?
NALM-6 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTZwOE[3OVQh|ryP NUfjd5pUW0GQR1XS
OCI-AML2 M3X4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnFTWM2OD15LkCwN|I3KM7:TR?= MnrlV2FPT0WU
SHP-77 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33EUWlEPTB;Nz6yNlQ{KM7:TR?= MoPRV2FPT0WU
NOMO-1 NITyeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fTSGlEPTB;Nz6yOFI2PCEQvF2= MWfTRW5ITVJ?
SK-N-DZ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXYNHQzUUN3ME23MlcyODh7IN88US=> M{D2WHNCVkeHUh?=
LB1047-RCC M{XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTdwN{KyN|Eh|ryP M1zRS3NCVkeHUh?=
MZ1-PC M3HsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoriTWM2OD15Lki2OVU5KM7:TR?= M2nDZnNCVkeHUh?=
NB10 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnYb4tKSzVyPUeuPVk2PTZizszN NF;ufnRUSU6JRWK=
RL95-2 NFTufm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL5bYJKSzVyPUiuNVA5PDJizszN NVnMV3BqW0GQR1XS
OMC-1 NFfkbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD16LkWyNVkyKM7:TR?= MV\TRW5ITVJ?
D-283MED MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2fGlEPTB;OD65NVcyQSEQvF2= NXnUeWJiW0GQR1XS
MC116 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvJdmJKSzVyPUiuPVc6PCEQvF2= M4TrZnNCVkeHUh?=
SJSA-1 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zv[WlEPTB;OT6wPVA6OSEQvF2= NGjoenlUSU6JRWK=
JiyoyeP-2003 NYH4RWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPOTWM2OD17LkK5N|E4KM7:TR?= MkTzV2FPT0WU
IST-MEL1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW1TWM2OD17Lke0NVk5KM7:TR?= NIDqOIhUSU6JRWK=
CTV-1 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n0SGlEPTB;MUCuNFk4QSEQvF2= NGXQPJFUSU6JRWK=
NH-12 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jOVmlEPTB;MUCuNlQ{OyEQvF2= NULWdnBHW0GQR1XS
CA46 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\Tc2lEPTB;MUCuN|YyKM7:TR?= MX7TRW5ITVJ?
NCI-SNU-1 NUS5[nhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5VIhKSzVyPUGwMlQ6PjlizszN MojWV2FPT0WU
SCLC-21H NW\B[2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS4S4pbUUN3ME2xNE43PTl4IN88US=> NIXaXm9USU6JRWK=
EC-GI-10 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KxcWlEPTB;MUCuO|A{OSEQvF2= M1TsTXNCVkeHUh?=
SR M3vz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXxTWM2OD1zMT6wNVg2KM7:TR?= MkHMV2FPT0WU
NCI-H1648 NX[0PXpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnwTWM2OD1zMT6wPVY2KM7:TR?= M2eyPHNCVkeHUh?=
TGBC1TKB M1TGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;xTWM2OD1zMT60NVAzKM7:TR?= MXTTRW5ITVJ?
EW-11 M4\xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvYTWM2OD1zMT61NVg3KM7:TR?= NETxbpRUSU6JRWK=
SK-MM-2 NHrUemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vRZWlEPTB;MUGuPFA3OSEQvF2= NW\lTGxZW0GQR1XS
NCI-H524 NISwd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\YOmlEPTB;MUGuPVgzOiEQvF2= MUDTRW5ITVJ?
NOS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTKTWM2OD1zMj6wN|Q2KM7:TR?= MoPiV2FPT0WU
AM-38 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX6TWM2OD1zMj61OlM{KM7:TR?= MnizV2FPT0WU
A498 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rnfWlEPTB;MUKuO|A3QSEQvF2= MkfRV2FPT0WU
KARPAS-422 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF{Lke0PVYh|ryP NFfadJBUSU6JRWK=
LU-139 M3[2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF{LkmwNlYh|ryP M3;KXHNCVkeHUh?=
COR-L88 M1\udWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWxdFJKSzVyPUGyMlk{QDJizszN M2jVR3NCVkeHUh?=
K5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0eZlKSzVyPUGyMlk1PjJizszN MkLxV2FPT0WU
NB13 M1n4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonQTWM2OD1zMj65O|g{KM7:TR?= M{T6PXNCVkeHUh?=
MRK-nu-1 M3jjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF|LkG5OUDPxE1? M4fQPXNCVkeHUh?=
MHH-NB-11 NGDZXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nyRWlEPTB;MUOuNlkxOiEQvF2= MoS5V2FPT0WU
KU812 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPTFU6UUN3ME2xN{43OTJ2IN88US=> MWHTRW5ITVJ?
TE-12 M1\Ce2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF|Lk[5PVQh|ryP Mn7pV2FPT0WU
NCI-N87 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF|LkezOkDPxE1? Ml32V2FPT0WU
EB2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjzcGZKSzVyPUGzMlg2ODVizszN NWXvcJc5W0GQR1XS
DB MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTFVHdKSzVyPUGzMlk5QDVizszN NUjnbVJ5W0GQR1XS
697 NXnFPJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\tVZZFUUN3ME2xOE41PTFzIN88US=> MYTTRW5ITVJ?
MSTO-211H NV7LeoJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ITWM2OD1zND63OFQ5KM7:TR?= NY[zd5dwW0GQR1XS
JVM-2 NH3VcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1njeGlEPTB;MUSuO|c{PSEQvF2= M4\Q[HNCVkeHUh?=
COLO-824 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HQNGlEPTB;MUSuO|k6PCEQvF2= NXTLOoE3W0GQR1XS
BC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K0RmlEPTB;MUWuN|k5KM7:TR?= NFm2T3ZUSU6JRWK=
BOKU NUnRS2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZTWM2OD1zNT65OlA5KM7:TR?= M2TOS3NCVkeHUh?=
GOTO NWnYSGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjwSGZsUUN3ME2xOk46PjF5IN88US=> NYrxR2k4W0GQR1XS
HCC2157 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXZT|dKSzVyPUG3MlQ4PTVizszN M4DWV3NCVkeHUh?=
LS-1034 NGfqb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jOfmlEPTB;MUeuOlgyQCEQvF2= NWi1VZZvW0GQR1XS
CAL-148 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTrU401UUN3ME2xO{46Pzl4IN88US=> M4Xq[XNCVkeHUh?=
MOLT-4 NYPZXmhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjlTWM2OD1zOD64NlA5KM7:TR?= NV\i[HJTW0GQR1XS
Daudi NX7IcIRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP6TWM2OD1zOD65NlMyKM7:TR?= NH;LT5JUSU6JRWK=
J-RT3-T3-5 M{PDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXI[ZJKSzVyPUG5MlQxPjZizszN MWfTRW5ITVJ?
KMOE-2 NFzFUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLNTWM2OD1zOT62OFgzKM7:TR?= NXPLTJdWW0GQR1XS
HL-60 NYrOZYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJfGlEPTB;MkCuNVk3PSEQvF2= NHPhUWFUSU6JRWK=
P31-FUJ MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELwc5JKSzVyPUKwMlQ4PTNizszN NGOxN4xUSU6JRWK=
IM-9 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfwbpBmUUN3ME2yNE43OjJ2IN88US=> NF7RW2VUSU6JRWK=
HDLM-2 NXrOPVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJyLki4NlEh|ryP M{fteHNCVkeHUh?=
NCI-H1304 M4q2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYezcmpxUUN3ME2yNU4xOzFzIN88US=> NUPTWGlHW0GQR1XS
NCI-H345 NVvqcII4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW4ZmsyUUN3ME2yNU4xPjR|IN88US=> NIfvfIRUSU6JRWK=
RPMI-6666 NIHibHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm4PWhqUUN3ME2yNU4{PjB{IN88US=> NF7UZ2dUSU6JRWK=
GR-ST M4OzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJzLkSxO{DPxE1? MULTRW5ITVJ?
CHP-126 M3X2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LlemlEPTB;MkGuOlE5OSEQvF2= NXvSfm5vW0GQR1XS
EHEB MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJzLk[3N|Eh|ryP NYfCSJdLW0GQR1XS
CPC-N MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnTWJZKSzVyPUK0MlAzODFizszN MmSxV2FPT0WU
NB1 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2Lk[5N|kh|ryP MVjTRW5ITVJ?
LS-123 NITpXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfXOYxKSzVyPUK0MlkxOTJizszN Mlv1V2FPT0WU
ST486 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHrUmpKSzVyPUK1MlEyOTNizszN NHrRTJpUSU6JRWK=
NCI-H1963 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ4LkC2NlMh|ryP MnHWV2FPT0WU
U-87-MG MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH2OZdYUUN3ME2yOk44PjR2IN88US=> NVfuelZQW0GQR1XS
COR-L279 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H6N2lEPTB;Mk[uO|kzOiEQvF2= MmW5V2FPT0WU
LU-165 M2f0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ZO4h5UUN3ME2yPE4xQDZzIN88US=> NHLHWndUSU6JRWK=
COLO-800 NHKxc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHkTWM2OD1{OD6yPVU3KM7:TR?= MUnTRW5ITVJ?
ETK-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ6LkO0OFYh|ryP NISwfm9USU6JRWK=
LNCaP-Clone-FGC MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDOSGVKSzVyPUK5MlkzQDFizszN NVXrdohZW0GQR1XS
SIG-M5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\LTWM2OD1|MD63PVUzKM7:TR?= NYDmRZhGW0GQR1XS
NB6 NGThZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17LVmlEPTB;M{CuPVUxOyEQvF2= NELDN2dUSU6JRWK=
NCI-H2107 NFfnNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe1PYtKSzVyPUOxMlI{OzhizszN NHT3[2FUSU6JRWK=
SNU-C1 NWiwN3BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrYVmxKUUN3ME2zNU4{OTJ4IN88US=> MkXPV2FPT0WU
JAR NUHLZplUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XMb2lEPTB;M{GuN|c6QSEQvF2= MVvTRW5ITVJ?
L-363 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjOVZJKSzVyPUOyMlIyPDRizszN MYnTRW5ITVJ?
EW-24 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN{LkO0O|Qh|ryP NYDkenc4W0GQR1XS
NB69 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS2cmFKSzVyPUOzMlY1PTRizszN M13ufHNCVkeHUh?=
EW-13 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fubWlEPTB;M{OuPFk3QSEQvF2= NV20dJloW0GQR1XS
Ramos-2G6-4C10 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD1TWM2OD1|ND6yPVk{KM7:TR?= NUjSXG06W0GQR1XS
TE-11 MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvXTWM2OD1|ND60PFIzKM7:TR?= MYrTRW5ITVJ?
L-428 NX7mR2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G4VWlEPTB;M{SuO|U{PiEQvF2= MWXTRW5ITVJ?
KP-N-YN M1fa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33GWmlEPTB;M{SuPVA2PyEQvF2= MVfTRW5ITVJ?
CGTH-W-1 NYTzbWd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnflTWM2OD1|Nj65NFQ5KM7:TR?= MWPTRW5ITVJ?
K-562 NHLVXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fJfGlEPTB;M{euNFg3PCEQvF2= NYi1bFFzW0GQR1XS
NCI-H1299 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfWTWM2OD1|OD6xOlA{KM7:TR?= NGTOZ|NUSU6JRWK=
RCC10RGB NInDO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjXUJNKSzVyPUO4MlIxQDNizszN MYHTRW5ITVJ?
NCI-SNU-16 NW\W[5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;QepYzUUN3ME2zPE42PjV|IN88US=> NXLEb2lCW0GQR1XS
LC-2-ad MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTN7LkSzN|ch|ryP M1\sWnNCVkeHUh?=
MHH-PREB-1 M32wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN7LkezPFgh|ryP M2f4WXNCVkeHUh?=
NCI-H64 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP0TXJKSzVyPUSwMlA6PDhizszN MVfTRW5ITVJ?
LB996-RCC M1f6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzlO|dKSzVyPUSwMlg4OTZizszN MVvTRW5ITVJ?
DEL MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj0XFRKSzVyPUSxMlQ1ODVizszN MVTTRW5ITVJ?
MLMA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ZW3BKSzVyPUSxMlc2QTVizszN Ml61V2FPT0WU
SBC-1 NH[zTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR{LkG4NFYh|ryP M33jXXNCVkeHUh?=
MPP-89 NX\jOJg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnLTWM2OD12Mj61PFc2KM7:TR?= NIT4OlhUSU6JRWK=
MV-4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR{LkmwOlch|ryP M3\KTnNCVkeHUh?=
EoL-1- NWjt[FNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;GZWlEPTB;NESuNVU3QCEQvF2= M3vq[nNCVkeHUh?=
CW-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR2LkizOFIh|ryP NFGxeopUSU6JRWK=
HT NGDSTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR3LkewNFch|ryP NIHrbpJUSU6JRWK=
SW954 M3m0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR5LkSxNlgh|ryP M3vVbnNCVkeHUh?=
A3-KAW Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLhTWM2OD12OT64NFYyKM7:TR?= M{TFVnNCVkeHUh?=
TC-YIK NXvkeXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Kd4RKSzVyPUWwMlA{PjNizszN NWHYZ3Q4W0GQR1XS
SW962 M3K4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofYTWM2OD13ND64N|U4KM7:TR?= NWHCR5NZW0GQR1XS
KP-N-RT-BM-1 M1vYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXwTWM2OD13Nj62OlM5KM7:TR?= MmXPV2FPT0WU
NCI-H1395 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmTWM2OD13OD64NVczKM7:TR?= NVz1c|ZxW0GQR1XS
RPMI-8402 NXi2Wm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fvOGlEPTB;NUiuPVUzPiEQvF2= NYS1Tm9TW0GQR1XS
SCH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\VXlNKSzVyPU[wMlk3OzhizszN NYq1d2pDW0GQR1XS
NCI-H2196 NEPHWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrMN4FKSzVyPU[xMlI{OSEQvF2= NInWcG5USU6JRWK=
LOXIMVI M1LEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TYbmlEPTB;NkGuPFI3PiEQvF2= M4jyRnNCVkeHUh?=
TGBC24TKB Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjVfIVKSzVyPU[yMlE1QTFizszN NWO5SY1xW0GQR1XS
SK-MEL-2 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXSTWM2OD14Mz65PFkzKM7:TR?= M4f1[nNCVkeHUh?=
U-698-M NHPnN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\zTWM2OD14OD61Olg4KM7:TR?= MYDTRW5ITVJ?
NCI-H1522 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjISVNKSzVyPU[5MlAxPDdizszN MXLTRW5ITVJ?
UACC-812 NH[2W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknDTWM2OD14OT61NlA6KM7:TR?= MXXTRW5ITVJ?
MHH-CALL-2 NX;CbHhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKxcYN[UUN3ME23NE4xPiEQvF2= NXHTVndjW0GQR1XS
NB5 NXT5[2FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz2TWM2OD15MD6zOFY5KM7:TR?= NHfRVZBUSU6JRWK=
KARPAS-299 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0NGlEPTB;N{CuOFQ1PyEQvF2= MW\TRW5ITVJ?
NCI-H1694 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjqZ3JKSzVyPUexMlA{OiEQvF2= NHn1THpUSU6JRWK=
NCI-H82 NVr2R4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\NTWM2OD15MT65OVA4KM7:TR?= M{eycHNCVkeHUh?=
SCC-15 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\iTWM2OD15Mj6zOEDPxE1? Ml7IV2FPT0WU
NCI-H1436 NECxSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn5VHE6UUN3ME23Nk44PDV4IN88US=> MVHTRW5ITVJ?
ATN-1 M2r2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLZTHRKSzVyPUe0MlUxPSEQvF2= Mk\IV2FPT0WU
RPMI-8866 NELFWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\pTWM2OD15ND63OVA6KM7:TR?= MVTTRW5ITVJ?
HCC1599 M{e4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrScFZKSzVyPUe0Mlg4OzJizszN NVz6eplrW0GQR1XS
NCI-H1155 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTqTWM2OD15ND65N|Y4KM7:TR?= NIjjcYNUSU6JRWK=
DOHH-2 NFPpO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTNbG9DUUN3ME23OE46PTF2IN88US=> NEfGeplUSU6JRWK=
SK-NEP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLr[4NKSzVyPUe1MlA4PTRizszN NXe1SItKW0GQR1XS
HCC1187 NY[1NGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKwN4c6UUN3ME23O{43OTJ{IN88US=> M2rUZnNCVkeHUh?=
NCI-H322M NX:wb2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fMbWlEPTB;N{iuN|cxQSEQvF2= NWK3UlhUW0GQR1XS
NCI-H526 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLpTWM2OD15OD61PFc4KM7:TR?= NUjEXmJMW0GQR1XS
NCI-H2171 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HteWlEPTB;N{muOFE{PiEQvF2= NEPW[VVUSU6JRWK=
COLO-668 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHqfmZKSzVyPUixMlU5QDRizszN MYrTRW5ITVJ?
RS4-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTzTWM2OD16Mj6yOVA2KM7:TR?= MmDMV2FPT0WU
NCI-H716 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3hXVZvUUN3ME24Nk46ODd3IN88US=> MWjTRW5ITVJ?
LU-134-A NUXjZYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\SPXNKSzVyPUizMlE{PTFizszN NVXtNXJjW0GQR1XS
RPMI-8226 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTTXXhKSzVyPUi0MlIyODdizszN MVTTRW5ITVJ?
KY821 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTlzLk[1OVEh|ryP MlW4V2FPT0WU
ECC4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD17Mz64NlY6KM7:TR?= M{iwZ3NCVkeHUh?=
EW-3 M3rnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTl2LkmwPFEh|ryP MmC5V2FPT0WU
NB7 NXXLdIU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fRSmlEPTB;OUWuO|c5PiEQvF2= NUXlN49EW0GQR1XS
NCI-H720 M1SwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTl6LkSwOlEh|ryP MVzTRW5ITVJ?
NCI-H446 NULhfod6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXjTWM2OD17OT63OVg5KM7:TR?= NY\O[3oxW0GQR1XS
NCI-H889 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjdXpKSzVyPUGwOE4zPDJizszN MkLFV2FPT0WU
EW-22 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX35NXczUUN3ME2xNFYvOTlizszN M2jYZ3NCVkeHUh?=
BV-173 NF;FVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFyOD63Nlgh|ryP MmjWV2FPT0WU
WSU-NHL M4PLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH3VpVKSzVyPUGwPU43PzFizszN MV7TRW5ITVJ?
MN-60 NFy0UoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL2eG9KSzVyPUGwPU43QSEQvF2= MULTRW5ITVJ?
DG-75 M4LkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\BZm9[UUN3ME2xNVMvOzV{IN88US=> MlnXV2FPT0WU
DMS-79 NGOyeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjs[nZKSzVyPUGxO{4{QDJizszN NVf6c2F[W0GQR1XS
SK-MEL-1 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFzOD6wNFkh|ryP M4faVHNCVkeHUh?=
DMS-153 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ewRmlEPTB;MUKxMlc1PSEQvF2= NV74dGFqW0GQR1XS
NCI-H510A NEXnVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\uXHZwUUN3ME2xNlcvOzJizszN MXvTRW5ITVJ?
BE-13 NIfEboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf2NGpKSzVyPUGzOE4xPDRizszN NUOwVnZxW0GQR1XS
KP-N-YS NVzhZpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorZTWM2OD1zM{muO|M3KM7:TR?= M3zxdXNCVkeHUh?=
SUP-T1 NHi5eVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHs[2lKSzVyPUG0N{44ODhizszN M3TMfHNCVkeHUh?=
EW-12 NELUNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jafWlEPTB;MUS0MlY6QSEQvF2= NFzQRZRUSU6JRWK=
NB14 NEKxXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPLepJKSzVyPUG0O{4xQDJizszN NX\4WXR7W0GQR1XS
MDA-MB-134-VI NFriZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF2OD6yOlgh|ryP MnnIV2FPT0WU
NCI-H1770 NYHYU2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vzeWlEPTB;MUW2MlI4QSEQvF2= M1q2NnNCVkeHUh?=
TUR NH3VTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWzbVlUUUN3ME2xOlcvQDdizszN MVjTRW5ITVJ?
NCI-H1417 M1vDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF6MD6zN|Eh|ryP M{TLNnNCVkeHUh?=
IMR-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD1zOEGuOVcyKM7:TR?= NFLwZW9USU6JRWK=
NCI-H226 NI\LNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[5TWM2OD1zOEiuPFY3KM7:TR?= M1vyb3NCVkeHUh?=
NCI-H187 NIPSOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLROFhJUUN3ME2xPVAvODZ2IN88US=> NYHIeHJqW0GQR1XS
SF539 M3;WXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHRTWM2OD1zOUKuO|I5KM7:TR?= M{LleHNCVkeHUh?=
TALL-1 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF7OD6zNFQh|ryP MWLTRW5ITVJ?
TE-441-T M33Mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D1[2lEPTB;MUm5Mlc{QSEQvF2= Mlf5V2FPT0WU
REH MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7qOWJKSzVyPUKzOk43OjZizszN NUD2XnNTW0GQR1XS
MS-1 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LN[WlEPTB;MkO5MlEzOSEQvF2= NGDqblNUSU6JRWK=
THP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ4ND63N|gh|ryP M1XtVHNCVkeHUh?=
NCI-H1838 M2Todmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3W4lKSzVyPUK3NU41PTZizszN MUTTRW5ITVJ?
P30-OHK NFz3d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDXWIVoUUN3ME2yPFMvQDR5IN88US=> Ml7ZV2FPT0WU
C8166 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7O[HlKSzVyPUO0OU4{OzhizszN MV;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID